Validations: Bracketing/Matrixing at Portfolio Level

Bridging New Strengths/Forms into Existing Designs Introduction to Stability Program Scale-Up The stability of pharmaceutical products is critical for ensuring their safety, efficacy, and quality throughout their lifecycle. In an era of rapid technological advancements and evolving patient needs, a stability program scale-up becomes essential. This guide aims to provide a comprehensive overview of how to bridge new strengths and…

Matrixing for Biologics vs Small Molecules Matrixing for Biologics vs Small Molecules In the rapidly evolving pharmaceutical landscape, ensuring the stability of both biologics and small molecule drugs is paramount for regulatory compliance and product integrity. This article provides a comprehensive, step-by-step tutorial on matrixing as part of a stability program scale-up strategy, focusing on the intricate differences between biologics…

Portfolio-Level Bracketing: Strengths, Packs, and Markets Portfolio-Level Bracketing: Strengths, Packs, and Markets In the competitive landscape of pharmaceutical development, a robust stability program is crucial for ensuring the quality and efficacy of products. This article will guide you through the intricacies of portfolio-level bracketing, addressing the strengths, packs, and markets with a focused lens on regulatory compliance in the US,…

Matrixing Designs That Survive Review: Smart Reductions The modern pharmaceutical landscape is defined by stringent regulatory requirements and complex programs aimed at ensuring product stability throughout the shelf life. Among the crucial methodologies employed, bracketing and matrixing represent pivotal strategies in the stability program scale-up. This tutorial acts as a comprehensive guide to the principles and practices of bracketing and…

Setting AET/DBT for Matrixing Decisions Introduction to Stability Program Scale-Up The pharmaceutical industry heavily relies on stability studies to ensure that products remain safe and efficacious throughout their shelf life. An integral part of these studies is the establishment of appropriate Accelerated Expiry Time (AET) and Design-Based Time (DBT) for matrixing decisions. The stability program scale-up process entails designing a…